Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 337

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Open access
Rothe, Achim, Sasse, Stephanie, Topp, Max S., Eichenauer, Dennis A., Hummel, Horst, Reiners, Katrin S., Dietlein, Markus, Kuhnert, Georg, Kessler, Joerg, Buerkle, Carolin, Ravic, Miroslav, Knackmuss, Stefan, Marschner, Jens-Peter, Pogge von Strandmann, Elke, Borchmann, Peter, Engert, Andreas·2015·Blood

Abstract

Key Points: The bispecific, tetravalent antibody AFM13 represents a new approach engaging natural killer cells via CD16A to fight CD30+ malignancies. AFM13 is well tolerated and active in Hodgkin lymphoma patients who received all standard therapies, including brentuximab vedotin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2014-12-614636

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 337

Metadata

Authors
Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., Ravic, M., Knackmuss, S., Marschner, J.-P., Pogge von Strandmann, E., Borchmann, P., & Engert, A.
Venue
Blood
Published
2015-06-25
Volume
125
Issue
26
Pages
4024-4031
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2123023182
Cited by
337
References
29
FWCI
19.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. https://app.cochat.ai/papers/10.1182/blood-2014-12-614636
The paper
Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., Ravic, M., Knackmuss, S., Marschner, J.-P., Pogge von Strandmann, E., Borchmann, P., & Engert, A. (2015). A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2014-12-614636

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.